JP2006290782A - Antiedemic composition - Google Patents

Antiedemic composition Download PDF

Info

Publication number
JP2006290782A
JP2006290782A JP2005112262A JP2005112262A JP2006290782A JP 2006290782 A JP2006290782 A JP 2006290782A JP 2005112262 A JP2005112262 A JP 2005112262A JP 2005112262 A JP2005112262 A JP 2005112262A JP 2006290782 A JP2006290782 A JP 2006290782A
Authority
JP
Japan
Prior art keywords
extract
component
drink
composition
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2005112262A
Other languages
Japanese (ja)
Inventor
Keiko Ikumura
慶子 生村
Taizo Seki
泰三 関
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Noevir Co Ltd
Tokiwa Pharmaceutical Co Ltd
Original Assignee
Tokiwa Yakuhin Kogyo KK
Noevir Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tokiwa Yakuhin Kogyo KK, Noevir Co Ltd filed Critical Tokiwa Yakuhin Kogyo KK
Priority to JP2005112262A priority Critical patent/JP2006290782A/en
Publication of JP2006290782A publication Critical patent/JP2006290782A/en
Pending legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To provide an oral agent having high effect on prophylaxis and improvement of edema, namely an antiedemic composition. <P>SOLUTION: The antiedemic composition is prepared by formulating, in good balance, at least an extract of Melilotus officinalis containing a coumarin or its derivatives as a first component with an extract derived from natural products, selected from a group consisting of Fucus vesiculosus, Piper retrofractum, Coix lachryma-jobi L., Humulus lupulus and Aloe vera and promoting metabolism as a second component and a vitamin B group as a third component. <P>COPYRIGHT: (C)2007,JPO&INPIT

Description

本発明は、浮腫の予防または改善に有用な抗浮腫組成物に関する。   The present invention relates to an anti-edema composition useful for preventing or ameliorating edema.

長時間の立位、座位などによって自然発生的に身体局所、特に、下肢に浮腫が発生する。浮腫とは、血管外の細胞外液(組織間質液)が組織間隙に過剰に貯留した状態をいい、一般的にはむくみと呼ばれる。このむくみは、疲労感をもたらすとともに、靴が履けなくなるなどの物理的障害をもたらし、このような状況に悩む人は少なくない。また、むくみは下肢静脈瘤とも関連する。   Due to long standing, sitting, etc., edema occurs spontaneously in the body, especially in the lower limbs. Edema refers to a state where extra-cellular extracellular fluid (tissue interstitial fluid) is excessively stored in the tissue gap, and is generally referred to as swelling. This swelling causes a feeling of fatigue and physical obstacles such as the inability to wear shoes, and many people suffer from such a situation. Swelling is also associated with lower limb varices.

これらのむくみを改善するため、メリロート(Melilotus officinalis)やブッチャーズブルーム(Ruscus aculeatus L.)のエキスを含有する利尿薬や漢方薬が広く用いられている。
メリロートは、セイヨウエビラハギとも呼ばれる豆科の植物であり、クマリン、ルチン、フラボン類を含む。特に、クマリンおよびルチンは浮腫改善に有用であることから、ヨーロッパでは、古くから下肢静脈瘤の改善薬としてメリロートのエキスが使用されてきた。
また、ブッチャーズブルームは、ナギイカダとも呼ばれる地中海に生育するユリ科の植物であり、血行促進や浮腫改善に有用であることが知られている。
In order to improve these swellings, diuretics and herbal medicines containing extracts of Merilotus officinalis and Butchers bloom (Ruscus aculeatus L.) are widely used.
Merirot is a leguminous plant also called shrimp, and includes coumarin, rutin, and flavones. In particular, since coumarin and rutin are useful for improving edema, the extract of Merrilot has long been used in Europe as an ameliorating agent for varicose veins.
Butcher's bloom is a lily family plant that grows in the Mediterranean Sea, also known as Nagikada, and is known to be useful for promoting blood circulation and improving edema.

セイヨウエビラハギ等のクマリン類またはその誘導体を含む植物と分岐鎖アミノ酸とを含む足のむくみの予防または改善用の食品組成物が、特許第3310649号明細書(特許文献1)に開示されている。
また、ブッチャーズブルームエキスとγ−トコフェロールとを有効成分とする利尿剤が、特開2002−226388号公報(特許文献2)に開示されている。
さらに、体液循環の改善、すなわちむくみを解消する作用を有する経口剤が特開2004−359674号公報(特許文献3)に開示され、この経口剤は、クマリン類またはその誘導体を含む植物であるセイヨウエビラハギ等とブッチャーズブルームとを含有する。
Japanese Patent No. 3310649 (Patent Document 1) discloses a food composition for the prevention or improvement of foot swelling comprising a plant containing coumarins such as shrimp or a derivative thereof and a branched chain amino acid. .
In addition, a diuretic containing a butcher's bloom extract and γ-tocopherol as active ingredients is disclosed in JP-A-2002-226388 (Patent Document 2).
Furthermore, an oral preparation having an action of improving body fluid circulation, ie, eliminating swelling, is disclosed in Japanese Patent Application Laid-Open No. 2004-359694 (Patent Document 3), and this oral preparation is a plant containing coumarins or derivatives thereof. Contains shrimp hagi and butchers bloom.

特許第3310649号明細書Japanese Patent No. 3310649 特開2002−226388号公報JP 2002-226388 A 特開2004−359674号公報JP 2004-359664 A

本発明者らは、むくみの予防・改善に対してより効果が高い経口剤、すなわち抗浮腫組成物の開発に鋭意研究を行った。その結果、意外なことに、第1の成分としてメリロートのエキスおよび第2の成分としてフーカスやヒハツ等の天然物由来のエキスとの混合物に、さらに第3の成分としてビタミンB群を添加することによって、下肢の疲労感やむくみに対する改善効果が促進されることを見出し、本発明を完成するに至った。   The inventors of the present invention have conducted intensive research on the development of an oral preparation having a higher effect on the prevention and improvement of swelling, that is, an anti-edema composition. As a result, surprisingly, the vitamin B group is added as a third component to a mixture of an extract of Merrilot as the first component and an extract derived from natural products such as fucus and hibatsu as the second component Has found that the effect of improving the fatigue and swelling of the lower limbs is promoted, and the present invention has been completed.

本発明は、少なくとも、第1成分として、メリロートエキス、第2成分として、フーカスエキス、ヒハツエキス、ハトムギエキス、ホップエキスおよびアロエベラエキスよりなる群から選択される天然物由来エキスまたはそれらの組合せ、および第3成分として、ビタミンB群を含む抗浮腫組成物を提供する。   The present invention includes, as a first component, a merryrot extract, a second component, a natural product-derived extract selected from the group consisting of fucus extract, hinoki extract, pearl barley extract, hop extract and aloe vera extract, or a combination thereof, and An anti-edema composition containing vitamin B group as three components is provided.

フーカス(Fucus vesiculosus)は、ヒバマタとも呼ばれる北海の北欧諸国沿岸および大西洋沿岸の岩に固着する海草(褐藻類)であり、脂肪燃焼・血行促進に効果があり、新陳代謝を活発にすることが知られている。
ヒハツ(Piper retrofractum)は、コショウ科南アジア原産のツル性木質植物であり、血管を拡張して血流を上げ、新陳代謝を促進することが知られている。
ハトムギ(Coix lachryma-jobi L.)は、イネ科の植物であり、利尿作用を有し、新陳代謝を促進する作用がある。
ホップ(Humulus lupulus)は、クワ科の植物であり、健胃、鎮静、利尿作用を有する。
アロエベラ(Aloe vera)は、ユリ科の多肉植物であり、抹消血管を拡張する作用、血管を柔軟にする作用、緩下利尿作用を有し、新陳代謝を盛んにすることが知られている。
Fucus (vesuculosus) is a seaweed (brown algae) that adheres to the rocks of the northern seas and the Atlantic coast of the North Sea, also known as Hibamata, and is known to be effective in promoting fat burning and blood circulation, and to activate metabolism. ing.
Hiperu (Piper retrofractum) is a creeping woody plant native to the pepper family South Asia, and is known to dilate blood vessels to increase blood flow and promote metabolism.
Barley (Coix lachryma-jobi L.) is a grass family plant, has a diuretic action, and has an action of promoting metabolism.
Hop (Humulus lupulus) is a plant of the mulberry family and has a healthy stomach, sedation, and diuretic action.
Aloe vera is a succulent plant of the lily family and has an action of expanding peripheral blood vessels, an action of softening blood vessels, and a laxative diuretic action, and is known to increase metabolism.

ビタミンB群は、穀物の胚芽、肝臓などに存在する水溶性ビタミンの一群であり、生体内の酵素反応の補酵素の構成成分として物質の代謝に関与する。
本発明に用いることができるビタミンB群は、塩酸チアミン、硝酸チアミン等のチアミン類;リボフラビン、リン酸リボフラビンナトリウム等のリボフラビン類;塩酸ピリドキシン等のピリドキシン類;ニコチン酸、ニコチン酸アミド等のニコチン酸類;パントテン酸ナトリウム、パントテン酸カルシウム等のパントテン酸類;またはそれらの組合せである。
The vitamin B group is a group of water-soluble vitamins present in cereal germs, livers, and the like, and is involved in the metabolism of substances as a component of coenzymes in enzyme reactions in vivo.
The vitamin B group that can be used in the present invention includes thiamines such as thiamine hydrochloride and thiamine nitrate; riboflavins such as riboflavin and sodium riboflavin phosphate; pyridoxines such as pyridoxine hydrochloride; nicotinic acids such as nicotinic acid and nicotinamide. Pantothenic acids such as sodium pantothenate and calcium pantothenate; or a combination thereof.

本発明の抗浮腫組成物は、例えば、ドリンク剤等の液状の形態や、顆粒剤、錠剤等の固形製剤などの様々な形態に加工することができる。
本発明の抗浮腫組成物をドリンク剤に加工する場合、上記の第1、第2および第3の成分に加えて、ドリンク剤を製造するために通常用いられる成分、例えば、果糖ブドウ糖液糖、ハチミツ、グラニュー糖、クエン酸、安息香酸ナトリウム、香料、精製水等を添加することができる。
また、本発明の抗浮腫組成物を顆粒剤や錠剤等の固形製剤に加工する場合、上記の第1ないし第3の成分に加えて、固形製剤を製造するために通常用いられる成分、例えば、乳糖、還元麦芽糖水飴、トウモロコシデンプンのごときデンプン、ヒドロキシプロピルセルロース、グリセリン脂肪酸エステル、香料等を添加することができる。
The anti-edema composition of the present invention can be processed into various forms such as liquid forms such as drinks and solid preparations such as granules and tablets.
When the anti-edema composition of the present invention is processed into a drink, in addition to the first, second and third components described above, ingredients commonly used for producing a drink, such as fructose glucose liquid sugar, Honey, granulated sugar, citric acid, sodium benzoate, fragrance, purified water and the like can be added.
In addition, when the anti-edema composition of the present invention is processed into a solid preparation such as a granule or a tablet, in addition to the above first to third components, ingredients commonly used for producing a solid preparation, for example, Lactose, reduced maltose starch syrup, starch such as corn starch, hydroxypropyl cellulose, glycerin fatty acid ester, fragrance and the like can be added.

本発明の抗浮腫組成物によれば、従来の抗浮腫組成物と比較して、足および脚を含む下肢のむくみおよび疲労感の改善に対してより高い効果を得ることができた。   According to the anti-edema composition of the present invention, it was possible to obtain a higher effect on the swelling of the lower limbs including feet and legs and the improvement of fatigue feeling as compared with the conventional anti-edema composition.

本発明の抗腫瘍組成物は、少なくとも、第1成分として、メリロートエキス、第2成分として、フーカスエキス、ヒハツエキス、ハトムギエキス、ホップエキスおよびアロエベラエキスよりなる群から選択される天然物由来エキスまたはそれらの組合せ、および第3成分として、塩酸チアミン、硝酸チアミン、リボフラビン、リン酸リボフラビンナトリウム、塩酸ピリドキシン、ニコチン酸、ニコチン酸アミド、パントテン酸ナトリウムおよびパントテン酸カルシウムよりなる群から選択されるビタミンB群またはそれらの組合せを含む。   The anti-tumor composition of the present invention comprises at least a natural product-derived extract selected from the group consisting of a merirot extract as a first component, a fucus extract, a chickweed extract, a pearl extract, a hop extract and an aloe vera extract as a second component, or those And, as a third component, a vitamin B group selected from the group consisting of thiamine hydrochloride, thiamine nitrate, riboflavin, sodium riboflavin phosphate, pyridoxine hydrochloride, nicotinic acid, nicotinamide, sodium pantothenate and calcium pantothenate Including combinations thereof.

本発明において、「エキス」とは天然物を圧搾や溶媒浸漬などの方法により得た搾汁や浸出液を濃縮したものを意味し、その濃縮の程度により、液体、半固体、または粉末状の固体の形態で得られるが、エキスが液体形態の場合、デキストリン等の賦形剤の添加によりエキス末にして使用することもできる。   In the present invention, “extract” means a product obtained by concentrating a juice or a leachate obtained by a method such as pressing or solvent immersion of a natural product, and depending on the degree of concentration, a liquid, semi-solid, or powdered solid However, when the extract is in a liquid form, it can also be used as an extract powder by adding excipients such as dextrin.

本発明に用いられるメリロート、フーカス、ヒハツ、ハトムギ、ホップおよびアロエベラなどの天然物由来のエキスを調製するとき、これらの天然物の使用部位は特に限定されず、全体または花、葉、茎、根、種子、果実、芽など特定の部位を生のまま、あるいは乾燥したものを用いることができる。
本発明において、上記の天然物をエキスとせずに、それら天然物を乾燥粉砕したものを直接用いることもできる。
本発明において、特に好ましく用いられる使用部位は、メリロートの地上部、フーカスの茎部、ヒハツの果穂、ハトムギの種子、ホップの果穂およびアロエベラの葉肉である。
When preparing extracts derived from natural products such as merirot, fucus, chickweed, pearl barley, hops and aloe vera used in the present invention, the use site of these natural products is not particularly limited, and the whole or flowers, leaves, stems, roots are used. Specific parts such as seeds, fruits and buds can be used raw or dried.
In the present invention, the natural products described above may be directly used after being dried and ground without using the natural products as extracts.
In the present invention, particularly preferably used parts are the above-ground part of Merirot, the stem part of Fucus, the ears of cypress, the seeds of pearl barley, the seeds of hops and the mesophyll of aloe vera.

本発明における天然物由来エキスは、生のままの使用部位またはその乾燥物を破砕または粉砕したものから抽出することができる。抽出は、例えば、圧搾、各種溶媒への浸漬などの通常用いられる方法により行うことができる。抽出に用いることができる溶媒は、水、エタノールのごとき低級アルコール、エーテル、アセトンなどの有機溶媒またはそれらの混合液を含む。   The natural product-derived extract in the present invention can be extracted from a raw use site or a product obtained by crushing or grinding a dried product thereof. Extraction can be performed by a commonly used method such as compression or immersion in various solvents. Solvents that can be used for extraction include water, organic solvents such as lower alcohols such as ethanol, ethers, acetone, or mixtures thereof.

実施例1
A.エキス調製
(1)メリロートエキスの調製
メリロートの地上部を乾燥し、粉砕したものにエタノール35体積%および水65体積%からなる35%エタノールを加えて抽出した。抽出液をろ過し、次いで、ろ液を減圧下で濃縮し、その濃縮物を精製した。精製物をスプレー乾燥して、メリロートエキスを得た。
Example 1
A. Extract Preparation (1) Preparation of Merirot Extract The ground part of Merirot was dried and pulverized, and extracted by adding 35% ethanol consisting of 35% by volume of ethanol and 65% by volume of water. The extract was filtered, then the filtrate was concentrated under reduced pressure and the concentrate was purified. The purified product was spray-dried to obtain a merirot extract.

(2)フーカスエキスの調製
フーカスの茎を乾燥し、粉砕したものに含水エタノールを加えて抽出した。抽出液をろ過し、次いで、ろ液を減圧下で濃縮した。その濃縮物を精製した。精製物をスプレー乾燥して、フーカスエキスを得た。
(2) Preparation of Fucus Extract Fucus stems were dried and pulverized and extracted with water-containing ethanol. The extract was filtered and then the filtrate was concentrated under reduced pressure. The concentrate was purified. The purified product was spray-dried to obtain a fucus extract.

(3)ヒハツエキスの調製
ヒハツの果穂を乾燥し、粉砕したものに熱水を加えて抽出した。抽出液をろ過し、次いで、ろ液を減圧下で濃縮した。その濃縮物を精製した。精製物をスプレー乾燥して、ヒハツエキスを得た。
(3) Preparation of Hihatsu Extract The ears of Hihatsu were dried and extracted by adding hot water to the pulverized one. The extract was filtered and then the filtrate was concentrated under reduced pressure. The concentrate was purified. The purified product was spray-dried to obtain a hihatsu extract.

(4)ハトムギエキスの調製
ハトムギの種子にエタノール30体積%および水70体積%からなる30%エタノールを加えて抽出した。この抽出を2回繰り返し、得られた抽出液を合わせてろ過し、次いで、ろ液を殺菌して、ハトムギエキスを得た。
(4) Preparation of pearl barley extract 30% ethanol consisting of 30 volume% ethanol and 70 volume% water was added to the pearl seed and extracted. This extraction was repeated twice, and the obtained extracts were combined and filtered, and then the filtrate was sterilized to obtain a barley extract.

(5)ホップエキスの調製
成熟したホップの果穂を粗砕したものにエタノール30体積%および水70体積%からなる30%エタノールを加えて抽出した。得られた抽出液をろ過し、次いで、ろ液を殺菌して、ホップエキスを得た。
(5) Preparation of hop extract 30% ethanol consisting of 30% by volume ethanol and 70% by volume water was added to the crushed fruit of mature hops for extraction. The obtained extract was filtered, and then the filtrate was sterilized to obtain a hop extract.

(6)アロエベラエキスの調製
アロエベラの葉肉を圧搾して得られた搾汁を減圧下で濃縮した。濃縮物を熱風乾燥または凍結乾燥して、アロエベラエキスを得た。
(6) Preparation of aloe vera extract The juice obtained by squeezing aloe vera mesophyll was concentrated under reduced pressure. The concentrate was dried with hot air or freeze-dried to obtain an aloe vera extract.

B.ドリンク剤の調製
メリロートエキス50mg、フーカスエキス50mg、クエン酸30mgおよび安息香酸ナトリウム1.2mgを精製水に溶解し、全量を2gとしてエキス調製液を調製した。
得られたエキス調製液、ニコチン酸アミド5mg、果糖ブドウ糖液1500mg、ハチミツ2000mg、グラニュー糖1000mg、クエン酸、安息香酸ナトリウムを精製水に溶解し、香料を加えた後、全量が50mLとなるようにさらに精製水を添加してドリンク剤を得た。このドリンク剤の最終的な配合を表1に示す。
また、このとき得られたドリンク剤のpHは3.1であり、目視観察により、沈殿や濁りは確認されなかった。
B. Preparation of a drink preparation An extract preparation solution was prepared by dissolving 50 mg of Merrilot extract, 50 mg of Fucus extract, 30 mg of citric acid and 1.2 mg of sodium benzoate in purified water to a total amount of 2 g.
The resulting extract preparation solution, nicotinamide 5 mg, fructose glucose solution 1500 mg, honey 2000 mg, granulated sugar 1000 mg, citric acid and sodium benzoate are dissolved in purified water, and after adding the fragrance, the total volume is 50 mL. Further, purified water was added to obtain a drink. The final formulation of this drink is shown in Table 1.
Moreover, pH of the drink obtained at this time was 3.1, and precipitation and turbidity were not confirmed by visual observation.

実施例2〜6
実施例1と同様にして、表1に示した配合のドリンク剤を得た。これらのドリンク剤のpHも全て3.1であり、目視観察により、沈殿や濁りは確認されなかった。
Examples 2-6
In the same manner as in Example 1, drinks having the formulations shown in Table 1 were obtained. The pH of these drinks was also 3.1, and no precipitation or turbidity was confirmed by visual observation.

Figure 2006290782
Figure 2006290782

比較例1〜6
実施例1と同様にして、表2に示した配合のドリンク剤を得た。これらのドリンク剤のpHも全て3.1であり、目視観察により、沈殿や濁りは確認されなかった。
Comparative Examples 1-6
In the same manner as in Example 1, drinks having the formulations shown in Table 2 were obtained. The pH of these drinks was also 3.1, and no precipitation or turbidity was confirmed by visual observation.

Figure 2006290782
Figure 2006290782

実施例7
メリロートエキス100mg、フーカスエキス100mg、クエン酸30mgおよび安息香酸ナトリウム1.2mgを精製水に溶解し、全量を2gとしてエキス調製液を調製した。
得られたエキス調製液、ニコチン酸アミド15mg、パントテン酸カルシウム30mg、果糖ブドウ糖液2000mg、ハチミツ2000mg、グラニュー糖1000mg、クエン酸、安息香酸ナトリウムを精製水に溶解し、香料を加えた後、全量が50mLとなるようにさらに精製水を添加してドリンク剤を得た。このドリンク剤の最終的な配合を表3に示す。
また、このとき得られたドリンク剤のpHは3.1であり、目視観察により、沈殿や濁りは確認されなかった。
Example 7
Mellilot extract 100 mg, Fucus extract 100 mg, citric acid 30 mg and sodium benzoate 1.2 mg were dissolved in purified water to prepare an extract preparation solution with a total amount of 2 g.
The resulting extract preparation solution, nicotinamide 15 mg, calcium pantothenate 30 mg, fructose glucose solution 2000 mg, honey 2000 mg, granulated sugar 1000 mg, citric acid, sodium benzoate are dissolved in purified water, and the total amount is added Purified water was further added so as to be 50 mL to obtain a drink. The final formulation of this drink is shown in Table 3.
Moreover, pH of the drink obtained at this time was 3.1, and precipitation and turbidity were not confirmed by visual observation.

実施例8〜11
実施例7と同様にして、表3に示した配合のドリンク剤を得た。これらのドリンク剤のpHも全て3.1であり、目視観察により、沈殿や濁りは確認されなかった。
Examples 8-11
In the same manner as in Example 7, drinks having the formulations shown in Table 3 were obtained. The pH of these drinks was also 3.1, and no precipitation or turbidity was confirmed by visual observation.

Figure 2006290782
Figure 2006290782

実施例12
メリロートエキス50mg、フーカスエキス50mg、ヒハツエキス50mg、ハトムギエキス5mg、ホップエキス5mg、アロエベラエキス3mg、クエン酸5mgおよび安息香酸ナトリウム1.2mgを精製水に溶解し、全量を2gとしてエキス調製液を調製した。
得られたエキス調製液、硝酸チアミン2mg、リン酸リボフラビンナトリウム2mg、塩酸ピリドキシン2mg、ニコチン酸アミド5mg、パントテン酸カルシウム5mg、果糖ブドウ糖液1500mg、ハチミツ2000mg、グラニュー糖1000mg、安息香酸ナトリウムを精製水に溶解し、香料を加えた後、全量が50mLとなるようにさらに精製水を添加してドリンク剤を得た。このドリンク剤の最終的な配合を表4に示す。
また、このドリンク剤のpHは4.0であり、目視観察により、沈殿や濁りは確認されなかった。
Example 12
Melilot extract 50 mg, Fucus extract 50 mg, pearl extract 50 mg, pearl extract 5 mg, hop extract 5 mg, aloe vera extract 3 mg, citric acid 5 mg and sodium benzoate 1.2 mg were dissolved in purified water to prepare an extract preparation solution with a total amount of 2 g. .
The resulting extract preparation solution, 2 mg thiamine nitrate, 2 mg sodium riboflavin phosphate, 2 mg pyridoxine hydrochloride, 5 mg nicotinic acid amide, 5 mg calcium pantothenate, 1500 mg fructose glucose solution, 2000 mg honey, 1000 mg granulated sugar, sodium benzoate in purified water After dissolving and adding a fragrance, purified water was further added so that the total amount became 50 mL to obtain a drink. The final formulation of this drink is shown in Table 4.
Moreover, pH of this drink was 4.0, and precipitation and turbidity were not confirmed by visual observation.

実施例13〜15
得られたエキス調製液にクエン酸を添加して、最終的なクエン酸の量を90mg、150mgまたは200mgにする以外は実施例12と同様にして、表4に示した配合のドリンク剤を得た。
実施例13〜15のドリンク剤のpHは、それぞれ、2.9、2.65、および2.2であった。いずれのドリンク剤においても、目視観察により、沈殿や濁りは確認されなかった。
Examples 13-15
A drink with the formulation shown in Table 4 was obtained in the same manner as in Example 12 except that citric acid was added to the resulting extract preparation to make the final amount of citric acid 90 mg, 150 mg or 200 mg. It was.
The pH values of the drinks of Examples 13 to 15 were 2.9, 2.65, and 2.2, respectively. In any of the drinks, no precipitation or turbidity was confirmed by visual observation.

Figure 2006290782
Figure 2006290782

実施例16
顆粒剤の調製
メリロートエキス、フーカスエキス、硝酸チアミン、リン酸リボフラビンナトリウム、塩酸ピリドキシン、乳糖、トウモロコシデンプンをそれぞれ篩過し、混合機にて混合する。得られた混合物に、ヒドロキシセルロースを精製水に溶解して調製した結合液を添加し、これを練合機にて練合した後、押出し造粒機にて造粒し、乾燥、整粒して、全量が1500mgの顆粒剤を得た。この顆粒剤の最終的な配合を表5に示す。
Example 16
Preparation of granules Merilot extract, fucus extract, thiamine nitrate, riboflavin sodium phosphate, pyridoxine hydrochloride, lactose and corn starch are each sieved and mixed in a mixer. To the obtained mixture, a binding solution prepared by dissolving hydroxycellulose in purified water is added, kneaded with a kneader, granulated with an extrusion granulator, dried and sized. As a result, granules having a total amount of 1500 mg were obtained. The final formulation of this granule is shown in Table 5.

実施例17〜20
実施例16と同様にして、表5に示した配合の顆粒剤を得た。
Examples 17-20
In the same manner as in Example 16, granules having the composition shown in Table 5 were obtained.

Figure 2006290782
Figure 2006290782

実施例21
錠剤の調製
メリロートエキス、フーカスエキス、ニコチン酸アミド、パントテン酸カルシウム、塩酸ピリドキシン、リン酸リボフラビンナトリウム、硝酸チアミン、還元麦芽糖水飴、トウモロコシデンプンをそれぞれ篩過した後、混合し、次いで、グリセリン脂肪酸エステルを添加して混合した。その後、打錠して、全量が650mgの錠剤を得た。この錠剤の最終的な配合を表6に示す。
Example 21
Preparation of tablets Merilot extract, fucus extract, nicotinic acid amide, calcium pantothenate, pyridoxine hydrochloride, sodium riboflavin phosphate, thiamine nitrate, reduced maltose starch syrup and corn starch were mixed and then mixed with glycerin fatty acid ester. Added and mixed. Thereafter, tableting was performed to obtain a tablet having a total amount of 650 mg. The final formulation of this tablet is shown in Table 6.

実施例22〜25
実施例21と同様にして、表6に示した配合の錠剤を得た。
Examples 22-25
In the same manner as in Example 21, tablets having the formulations shown in Table 6 were obtained.

Figure 2006290782
Figure 2006290782

実施例26
下肢のむくみおよび疲労感に対する改善効果
立ち仕事が多く、足および脚の下肢のむくみおよび疲労感の悩みをかかえている女性を対象として、実施例1〜6および比較例1〜6で調製したドリンク剤の下肢のむくみおよび疲労感に対する改善効果をモニターした。
具体的には、各ドリンク剤につき任意に選択した女性5名(n=5)に、仕事の合間に50mLのドリンク剤を摂取してもらい、仕事の終了後、下肢のむくみおよび疲労感の改善度合いについてアンケート調査した。改善度合いは、「非常に効果あり」、「効果あり」、「やや効果あり」および「効果なし」の4段階で評価してもらい、それぞれの点数を3、2、1および0点とした。各評価を行った人数を表7〜10に示し、点数にその点数を付けた人数を乗じて得られた値の合計点数も示した。
Example 26
Improvement effect on swelling and fatigue of lower limbs Drinks prepared in Examples 1-6 and Comparative Examples 1-6 for women who have a lot of standing work and suffer from swelling and fatigue of legs and legs. The effect of the agent on the swelling and fatigue of the lower limbs was monitored.
Specifically, 5 women (n = 5) arbitrarily selected for each drink were ingested 50 mL of drink between work, and after the work was completed, swelling of the lower limbs and improvement of fatigue A questionnaire survey was conducted on the degree. The degree of improvement was evaluated in four stages: “very effective”, “effective”, “somewhat effective”, and “no effect”, and the score was 3, 2, 1, and 0, respectively. The number of people who performed each evaluation is shown in Tables 7 to 10, and the total number of values obtained by multiplying the number of points by the number of points is also shown.

Figure 2006290782
Figure 2006290782

Figure 2006290782
Figure 2006290782

Figure 2006290782
Figure 2006290782

Figure 2006290782
Figure 2006290782

メリロートエキスである第1成分、フーカスエキス等の第2成分およびビタミンB群の第3成分の3つの成分が配合された実施例1〜6のドリンク剤では、10点を超える高い評価を得たが、上記3つの成分のいずれかが欠如している比較例1〜6で得られたドリンク剤は5点以下の低い評価しか得られなかった。例えば、比較例2のドリンク剤は、第1成分および第2成分を含有するが第3成分であるビタミンB群を含有しないため、4点の評価であった。また、比較例3〜6のドリンク剤は、第1成分および第3成分を含有するが第2成分を含有しないため、0〜2点の評価であった。
この結果から、第1成分、第2成分および第3成分の三成分をバランス良く含有する本発明の抗浮腫組成物は、下肢のむくみおよび疲労感を改善する効果が非常に高いことが分かった。
In the drinks of Examples 1 to 6 in which three components of the first component, which is a merirot extract, the second component such as a fucus extract, and the third component of the vitamin B group were blended, a high evaluation exceeding 10 points was obtained. However, the drinks obtained in Comparative Examples 1 to 6 lacking any of the above three components were only able to obtain a low evaluation of 5 points or less. For example, since the drink of Comparative Example 2 contains the first component and the second component but does not contain the vitamin B group that is the third component, the evaluation was four points. Moreover, since the drink of Comparative Examples 3-6 contains a 1st component and a 3rd component, but does not contain a 2nd component, it was evaluation of 0-2 points.
From this result, it was found that the anti-edema composition of the present invention containing the first component, the second component, and the third component in a well-balanced manner has a very high effect of improving swelling and fatigue of the lower limbs. .

実施例27
美肌効果
実施例7〜11のドリンク剤は、実施例1〜6のドリンク剤と比較して第1成分および第2成分をより多く含有する。これら実施例7〜11のドリンク剤を、一日50mL継続して1週間摂取してもらったところ、肌状態が良くなるなどの美肌効果が感じられたという回答が得られた。
すなわち、本発明の抗浮腫組成物は、第1成分および第2成分の配合量を調整することによって、下肢のむくみや疲労感に対する改善効果のみならず、美肌効果も有することが確認された。
Example 27
Beautiful skin effect The drinks of Examples 7-11 contain more 1st components and 2nd components compared with the drinks of Examples 1-6. When the drinks of Examples 7 to 11 were continuously taken for 50 weeks a day for 1 week, an answer that a skin-beautifying effect such as an improvement in skin condition was felt was obtained.
That is, it was confirmed that the anti-edema composition of the present invention has not only an improvement effect on swelling and fatigue of the lower limbs but also a skin beautifying effect by adjusting the blending amounts of the first component and the second component.

実施例28
保存安定性評価
ドリンク剤は、長期保存により濁りや沈殿が発生することがある。ドリンク剤中の濁りや沈殿の発生は、主に、ドリンク剤成分の凝集により引き起こされ、この凝集の発生はpHに依存することが知られている。
そこで、本発明のドリンク剤の経時安定性を確認するために、pHの異なる4種類のドリンク剤を用いて加速試験を実施した。
まず、実施例12〜15において、50mLのドリンク剤に含有されるクエン酸の配合量を5mgから200mgまで増加することによってpHを段階的に低下させたドリンク剤を調製した。なお、これらのドリンク剤において、クエン酸以外の成分の配合量は同一である。
各ドリンク剤の調製直後、および50℃の恒温槽中で保存して1月後、2月後および3月後に、ドリンク剤の濁りや沈殿の発生の状態を目視観察した。
各ドリンク剤に対するpHおよび各時期における目視観察結果を表11に示した。
Example 28
Storage stability evaluation Drinks may become turbid or precipitate after long-term storage. It is known that the occurrence of turbidity and precipitation in the drink is mainly caused by the aggregation of the drink component, and the occurrence of this aggregation depends on the pH.
Therefore, in order to confirm the temporal stability of the drink of the present invention, an acceleration test was performed using four kinds of drinks having different pHs.
First, in Examples 12-15, the drink which reduced pH stepwise by increasing the compounding quantity of the citric acid contained in 50 mL of drink from 5 mg to 200 mg was prepared. In these drinks, the amount of ingredients other than citric acid is the same.
Immediately after the preparation of each drink, and after 1 month, 2 months, and 3 months of storage in a thermostat at 50 ° C., the turbidity of the drink and the occurrence of precipitation were visually observed.
Table 11 shows the pH of each drink and the results of visual observation at each period.

Figure 2006290782
Figure 2006290782

表11によれば、ドリンク剤のpHが2.9以上であれば長期の保存安定性が良好であるが、pHが2.65を下回ると保存1月後には濁りが発生し、保存2月後には沈殿が生じることが確認された。   According to Table 11, long-term storage stability is good if the pH of the drink is 2.9 or higher, but if the pH is below 2.65, turbidity occurs after one month of storage, and storage February It was confirmed that precipitation occurred later.

実施例1〜11で得られたドリンク剤のpHは3.1であり、保存安定領域にある。かくして、本発明の抗浮腫組成物を用いれば、高い抗浮腫効果および美肌効果を有し、かつ、保存安定性が良好なドリンク剤を得ることができる。   The pH of the drinks obtained in Examples 1 to 11 is 3.1 and is in the storage stable region. Thus, by using the anti-edema composition of the present invention, it is possible to obtain a drink having a high anti-edema effect and a skin beautifying effect and good storage stability.

本発明の抗浮腫組成物を用いれば、従来の抗浮腫組成物よりも高い抗浮腫効果を有する製剤を得ることができ、また、本発明の抗浮腫組成物は、ドリンク剤等の液状の形態や、顆粒剤、錠剤等の固形製剤などの様々な形態に加工することができる。
When the anti-edema composition of the present invention is used, a preparation having an anti-edema effect higher than that of the conventional anti-edema composition can be obtained, and the anti-edema composition of the present invention is in a liquid form such as a drink. And can be processed into various forms such as solid preparations such as granules and tablets.

Claims (2)

少なくとも、第1成分として、メリロートエキス、第2成分として、フーカスエキス、ヒハツエキス、ハトムギエキス、ホップエキスおよびアロエベラエキスよりなる群から選択される天然物由来エキスまたはそれらの組合せ、および第3成分として、ビタミンB群を含む抗浮腫組成物。   As a first component, at least as a merorot extract, as a second component, a natural product-derived extract selected from the group consisting of fucus extract, hinoki extract, pearl barley extract, hop extract and aloe vera extract, or a combination thereof, and as a third component, An anti-edema composition comprising vitamin B group. ビタミンB群が、塩酸チアミン、硝酸チアミン、リボフラビン、リン酸リボフラビンナトリウム、塩酸ピリドキシン、ニコチン酸、ニコチン酸アミド、パントテン酸ナトリウム、パントテン酸カルシウムまたはそれらの組合せである請求項1記載の抗浮腫組成物。

The anti-edema composition according to claim 1, wherein the vitamin B group is thiamine hydrochloride, thiamine nitrate, riboflavin, riboflavin sodium phosphate, pyridoxine hydrochloride, nicotinic acid, nicotinic acid amide, sodium pantothenate, calcium pantothenate or a combination thereof. .

JP2005112262A 2005-04-08 2005-04-08 Antiedemic composition Pending JP2006290782A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2005112262A JP2006290782A (en) 2005-04-08 2005-04-08 Antiedemic composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005112262A JP2006290782A (en) 2005-04-08 2005-04-08 Antiedemic composition

Publications (1)

Publication Number Publication Date
JP2006290782A true JP2006290782A (en) 2006-10-26

Family

ID=37411742

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005112262A Pending JP2006290782A (en) 2005-04-08 2005-04-08 Antiedemic composition

Country Status (1)

Country Link
JP (1) JP2006290782A (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009173604A (en) * 2008-01-25 2009-08-06 Kobayashi Pharmaceut Co Ltd Tablet containing processed vegetable and pantethines
JP2011073973A (en) * 2009-09-29 2011-04-14 Shiseido Co Ltd Composition for ameliorating fatigue for menopause
JP2013209339A (en) * 2012-03-30 2013-10-10 Shiseido Co Ltd Apj activation agent
ITLE20130016A1 (en) * 2013-11-08 2015-05-09 Giellefarma Del Dr Luigi Gaglione FUNCTIONAL INCREASED FOR THE PREPARATION OF FOOD SUPPLEMENTS CONSISTING OF A MIXTURE OF VEGETABLE GLYCOSIDES BASED ON DIOSMINE, RUTIN, ESPERIDINE AND NATURAL CUMARIN OBTAINED FROM DRY MELILOTUM OFFICINAL USEFUL EXTRACT FOR TROFISMO DE
CN104661537A (en) * 2012-09-27 2015-05-27 三得利控股株式会社 Skin condition amelioration agent
CN105362768A (en) * 2015-12-08 2016-03-02 孙世林 Traditional Chinese medicine for treating wind-water fighting type edema
JP2020150953A (en) * 2013-09-13 2020-09-24 大正製薬株式会社 Beverage

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2513121A1 (en) * 1981-09-23 1983-03-25 Goemar Sa Medicaments contg. brown or red seaweed - for treatment of capillary fragility and permeability, and anti:aggregation agents
JP2000167017A (en) * 1998-12-07 2000-06-20 文子 ▲高▼山 Socks for eliminating swelling and languidness of leg during daily life, standing work, and pregnancy, and its manufacture
JP2003286129A (en) * 2002-03-27 2003-10-07 Hakugen:Kk Slimming sheet material
JP2004107245A (en) * 2002-09-17 2004-04-08 Fancl Corp Kit for improving drabness, shadow, and dropsy around eye
WO2004064818A1 (en) * 2003-01-17 2004-08-05 Kirin Beer Kabushiki Kaisha Blood pressure-lowering agent, vascular flexibility-improving agent and foods having these functions imparted thereto
JP2004359674A (en) * 2003-05-12 2004-12-24 Fancl Corp Kit for body weight reduction

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2513121A1 (en) * 1981-09-23 1983-03-25 Goemar Sa Medicaments contg. brown or red seaweed - for treatment of capillary fragility and permeability, and anti:aggregation agents
JP2000167017A (en) * 1998-12-07 2000-06-20 文子 ▲高▼山 Socks for eliminating swelling and languidness of leg during daily life, standing work, and pregnancy, and its manufacture
JP2003286129A (en) * 2002-03-27 2003-10-07 Hakugen:Kk Slimming sheet material
JP2004107245A (en) * 2002-09-17 2004-04-08 Fancl Corp Kit for improving drabness, shadow, and dropsy around eye
WO2004064818A1 (en) * 2003-01-17 2004-08-05 Kirin Beer Kabushiki Kaisha Blood pressure-lowering agent, vascular flexibility-improving agent and foods having these functions imparted thereto
JP2004359674A (en) * 2003-05-12 2004-12-24 Fancl Corp Kit for body weight reduction

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009173604A (en) * 2008-01-25 2009-08-06 Kobayashi Pharmaceut Co Ltd Tablet containing processed vegetable and pantethines
JP2011073973A (en) * 2009-09-29 2011-04-14 Shiseido Co Ltd Composition for ameliorating fatigue for menopause
JP2013209339A (en) * 2012-03-30 2013-10-10 Shiseido Co Ltd Apj activation agent
CN104661537A (en) * 2012-09-27 2015-05-27 三得利控股株式会社 Skin condition amelioration agent
JP2020150953A (en) * 2013-09-13 2020-09-24 大正製薬株式会社 Beverage
ITLE20130016A1 (en) * 2013-11-08 2015-05-09 Giellefarma Del Dr Luigi Gaglione FUNCTIONAL INCREASED FOR THE PREPARATION OF FOOD SUPPLEMENTS CONSISTING OF A MIXTURE OF VEGETABLE GLYCOSIDES BASED ON DIOSMINE, RUTIN, ESPERIDINE AND NATURAL CUMARIN OBTAINED FROM DRY MELILOTUM OFFICINAL USEFUL EXTRACT FOR TROFISMO DE
CN105362768A (en) * 2015-12-08 2016-03-02 孙世林 Traditional Chinese medicine for treating wind-water fighting type edema

Similar Documents

Publication Publication Date Title
JP2006290782A (en) Antiedemic composition
JP2006045212A (en) Oral composition containing specific quinic acid derivative
JP3768795B2 (en) Xanthine oxidase inhibitor
KR20160144791A (en) Composition for relieving menopausal symptom
JP2010265251A (en) Bloodstream-promoting/improving agent
JP2015127339A (en) Composition for anti-saccharification
JP2006036787A (en) Xanthine oxidase inhibitor
JP2007055951A (en) Body fat reducing agent
JP2010159283A (en) Proanthocyanidin-containing composition
JP2010265252A (en) Hair-restoring agent
JP2007063207A (en) Adiponectin production promoter
JP2005237291A (en) Health food
KR101768612B1 (en) Food composition for improving liver function and method of health tea using thereof
JP2015025008A (en) Anti-glycation composition
JP2008231008A (en) Composition having antioxidation action
JP2005060338A (en) Proanthocyanidin-including composition
JP6607418B2 (en) Anti-glycation composition
KR101872937B1 (en) Manufacturing method of Vitamin Composition
JP2007091630A (en) Food composition and oral skin ameliorating agent
KR101129685B1 (en) The Salicomia Herbaceal for the Atopic Dermatitis and the Method for Manufacturing Salicomia Herbaceal for the Atopic Dermatitis
CN102333529A (en) Coenzyme q10-containing composition for oral ingestion
JP6260804B2 (en) Anti-glycation composition
JP2006016340A (en) Blood uric acid level reduction agent having extract of punica granatum l. as active ingredient
JP2005350432A (en) Prostacyclin formation promoter
KR20150120741A (en) Composition for preventing or improving atopic dermatitis comprising mixture of persimmon peel, persimmon flesh, persimmon leaf and Diospyros lotus leaf as effective component

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110419

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110601

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110927

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120117